Global Urinary Catheters Companies

Latest Urinary Catheters Companies Update

• 
  Nov 2023: The cost-effectiveness watchdog for England, the National Institute for Health and Care Excellence, has completed draft guidance on hybrid closed-loop systems and concluded that to help people with Type 1 diabetes better manage their condition, the technology should be widely accessible and affordable. Closed-loop diabetes management systems, sometimes called artificial pancreas, combine insulin pumps and continuous glucose monitors. The continuous glucose monitor sends real-time blood sugar readings to the pump, which uses an algorithm to analyze them and adjust basal insulin dosages automatically. This eliminates the need for manual injections and ongoing glucose monitoring. However, users still need to provide some input to hybrid versions of such devices to schedule insulin bolus doses, submit a carbohydrate count at meals, or change other system parameters.

• 
  Nov 2023: To support its ongoing expansion, Coloplast, a market leader in intimate healthcare, plans to capitalize over 100 million euros in a new production facility in Portugal. Coloplast's intermittent catheters, which are used by patients with urine retention—such as those with spina bifida or spinal cord injuries—and who are unable to empty their bladder, will be manufactured at the new facility. Coloplast plans to use the new location to meet the growing demand for intermittent catheters worldwide, focusing on Europe, which makes up most of the company's revenues and is its largest market.

• Boston Scientific Corporation


• Coloplast A/S


• Convatec Group PLC


• Werkomed Pty Ltd


• Braun Melsungen AG


• DISA Vascular


• Medloyd Healthcare


• Terumo Europe NV


• Teleflex


• Medtronic


• R. Bard, Inc.